Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results
Nevro Corp. (NYSE: NVRO) has released preliminary, unaudited financial results for Q4 and full-year 2024. The company expects Q4 2024 worldwide revenue of $105-106 million, showing a 9-10% decrease compared to Q4 2023. Full-year 2024 worldwide revenue is anticipated at $408-409 million, representing a 4% year-over-year decrease.
Despite the decline, the full-year revenue exceeded previous guidance, primarily due to higher-than-expected spinal cord stimulation device replacement procedures in Q4. The company's cash position strengthened, with cash, cash equivalents, and short-term investments reaching approximately $292.5 million as of December 31, 2024, marking a $15.5 million increase from September 30, 2024.
Nevro continues to invest in direct-to-consumer advertising, expecting benefits to materialize throughout 2025, particularly in the second half. The company remains in ongoing discussions exploring strategic options to accelerate growth and enhance shareholder value.
Nevro Corp. (NYSE: NVRO) ha rilasciato risultati finanziari preliminari e non verificati per il quarto trimestre e l'anno intero 2024. L'azienda prevede un fatturato globale per il quarto trimestre 2024 di 105-106 milioni di dollari, mostrando una diminuzione del 9-10% rispetto al quarto trimestre 2023. Il fatturato globale per l'intero anno 2024 è previsto tra 408-409 milioni di dollari, rappresentando una diminuzione del 4% rispetto all'anno precedente.
Nonostante il calo, il fatturato dell'intero anno ha superato le indicazioni precedenti, principalmente a causa di un numero di interventi di sostituzione di dispositivi di stimolazione del midollo spinale superiore alle attese nel quarto trimestre. La posizione di cassa dell'azienda si è rafforzata, con liquidità, equivalenti di liquidità e investimenti a breve termine che hanno raggiunto circa 292,5 milioni di dollari al 31 dicembre 2024, segnando un aumento di 15,5 milioni di dollari rispetto al 30 settembre 2024.
Nevro continua a investire in pubblicità diretta al consumatore, aspettandosi che i benefici si materializzino nel corso del 2025, in particolare nella seconda metà. L'azienda è coinvolta in discussioni continue per esplorare opzioni strategiche volte ad accelerare la crescita e aumentare il valore per gli azionisti.
Nevro Corp. (NYSE: NVRO) ha publicado resultados financieros preliminares y no auditados para el cuarto trimestre y el año completo 2024. La compañía espera ingresos globales en el cuarto trimestre de 2024 de 105-106 millones de dólares, lo que representa una disminución del 9-10% en comparación con el cuarto trimestre de 2023. Se anticipa que los ingresos globales para todo el año 2024 sean de 408-409 millones de dólares, lo que representa una disminución del 4% en comparación con el año anterior.
A pesar de la disminución, los ingresos anuales superaron las proyecciones anteriores, principalmente debido a un número mayor al esperado de procedimientos de reemplazo de dispositivos de estimulación de la médula espinal en el cuarto trimestre. La posición de efectivo de la compañía se ha fortalecido, con efectivo, equivalentes de efectivo e inversiones a corto plazo alcanzando aproximadamente 292.5 millones de dólares al 31 de diciembre de 2024, marcando un aumento de 15.5 millones de dólares desde el 30 de septiembre de 2024.
Nevro continúa invirtiendo en publicidad directa al consumidor, esperando que los beneficios se materialicen a lo largo de 2025, particularmente en la segunda mitad. La compañía sigue en conversaciones continuas para explorar opciones estratégicas para acelerar el crecimiento y mejorar el valor para los accionistas.
네브로 코프(Nevro Corp.) (NYSE: NVRO)는 2024년 4분기 및 전체 연도에 대한 예비 비감사 재무 결과를 발표했습니다. 회사는 2024년 4분기 전 세계 매출이 1억 5천만~1억 6천만 달러에 이를 것으로 예상하며, 이는 2023년 4분기와 비교할 때 9-10% 감소한 수치입니다. 전체 연도 2024년 전 세계 매출은 4억 800만~4억 900만 달러로 예상되며, 이는 전년 대비 4% 감소한 수치입니다.
감소에도 불구하고 전체 연 매출은 이전 추정치를 초과했으며, 이는 주로 4분기에 예상보다 높은 척수 자극 장치 교체 절차 덕분입니다. 회사의 현금 위치는 강화되었으며, 2024년 12월 31일 기준으로 현금, 현금성 자산 및 단기 투자액이 약 2억 9천2백50만 달러에 달해 2024년 9월 30일보다 1천5백50만 달러 증가했습니다.
네브로는 소비자 직접 광고에 계속 투자하고 있으며, 2025년 동안, 특히 하반기에 혜택이 나타날 것으로 기대하고 있습니다. 회사는 성장을 가속화하고 주주 가치를 높이기 위한 전략적 옵션을 탐색하는 지속적인 논의에 참여하고 있습니다.
Nevro Corp. (NYSE: NVRO) a publié des résultats financiers préliminaires et non audités pour le quatrième trimestre et l'année complète 2024. La société s'attend à un chiffre d'affaires mondial pour le quatrième trimestre 2024 de 105-106 millions de dollars, ce qui représente une baisse de 9-10 % par rapport au quatrième trimestre 2023. Le chiffre d'affaires mondial pour l'année 2024 est anticipé entre 408-409 millions de dollars, représentant une diminution de 4 % d'une année sur l'autre.
Malgré cette baisse, le chiffre d'affaires annuel a dépassé les prévisions précédentes, principalement en raison d'un nombre de procédures de remplacement de dispositifs de stimulation de la moelle épinière supérieur aux attentes au quatrième trimestre. La situation de trésorerie de l'entreprise s'est renforcée, avec des liquidités, des équivalents de liquidités et des investissements à court terme atteignant environ 292,5 millions de dollars au 31 décembre 2024, soit une augmentation de 15,5 millions de dollars par rapport au 30 septembre 2024.
Nevro continue d'investir dans la publicité directe à destination des consommateurs, s'attendant à ce que les bénéfices se concrétisent tout au long de 2025, en particulier dans la seconde moitié. L'entreprise est également engagée dans des discussions continues pour explorer des options stratégiques visant à accélérer la croissance et à améliorer la valeur pour les actionnaires.
Nevro Corp. (NYSE: NVRO) hat vorläufige, unverbindliche Finanzzahlen für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht. Das Unternehmen erwartet im vierten Quartal 2024 weltweit Einnahmen von 105-106 Millionen US-Dollar, was einem Rückgang von 9-10% im Vergleich zum vierten Quartal 2023 entspricht. Für das Gesamtjahr 2024 werden die weltweiten Einnahmen auf 408-409 Millionen US-Dollar geschätzt, was einem Rückgang von 4% im Jahresvergleich entspricht.
Trotz des Rückgangs übertrafen die Gesamtjahreseinnahmen die vorherige Prognose, vor allem aufgrund höher als erwarteter Ersatzverfahren für Geräte zur Rückenmarksstimulation im vierten Quartal. Die Kapitalausstattung des Unternehmens hat sich verbessert, wobei Bargeld, Zahlungsmitteläquivalente und kurzfristige Investitionen zum 31. Dezember 2024 etwa 292,5 Millionen US-Dollar erreichten, was einem Anstieg von 15,5 Millionen US-Dollar seit dem 30. September 2024 entspricht.
Nevro investiert weiterhin in Direktwerbung für Verbraucher und erwartet, dass sich die Vorteile im Laufe des Jahres 2025, insbesondere in der zweiten Jahreshälfte, zeigen werden. Das Unternehmen befindet sich weiterhin in laufenden Gesprächen zur Erkundung strategischer Optionen zur Beschleunigung des Wachstums und zur Steigerung des Shareholder-Value.
- Cash position increased by $15.5 million in Q4 2024 to $292.5 million
- Full-year 2024 revenue exceeded previous guidance
- Higher-than-anticipated SCS device replacement procedures in Q4 2024
- Q4 2024 worldwide revenue decreased 9-10% year-over-year to $105-106 million
- Full-year 2024 worldwide revenue declined 4% to $408-409 million
- U.S. revenue decreased 4% for full-year 2024
Insights
The preliminary Q4 and FY2024 results reveal concerning trends for Nevro. Q4 worldwide revenue declined
The revenue beat against November guidance stems primarily from higher-than-expected SCS device replacement procedures, which typically generate lower margins than new implants and don't indicate organic growth. While the
The ongoing strategic review and DTC advertising initiative, with expected benefits in H2 2025, suggest management is actively seeking solutions but facing challenges in the core business. The medical device market's competitive dynamics and pricing pressures continue to impact Nevro's market position in the SCS segment.
The medical device sector's dynamics are particularly challenging for smaller players like Nevro, with its
The strategic review process hints at potential M&A activity, which could be important given the company's scale disadvantages. The delay in meaningful DTC advertising impact until H2 2025 creates a significant gap period where market share could further deteriorate. The positive cash position provides some strategic flexibility but may not be sufficient to fund aggressive growth initiatives without additional capital.
Cash, Cash Equivalents and Short-Term Investments Increased Approximately
Preliminary, Unaudited Financial Highlights
- Fourth-quarter 2024 worldwide revenue is expected to be approximately
$105 million $106 million 9% to10% on a reported and constant currency basis compared with the fourth quarter of 2023; fourth-quarter 2024 U.S. revenue is expected to be approximately$91 million $92 million 9% to10% compared with the fourth quarter of 2023. - Full-year 2024 worldwide revenue is expected to be approximately
$408 million $409 million 4% on a reported and constant currency basis compared with the full-year 2023; full-year 2024 U.S. revenue is expected to be approximately$352.5 million $353.5 million 4% decrease compared with full-year 2023. Full-year 2024 worldwide revenue is higher than the guidance the company provided in November 2024 primarily due to the impact of greater-than-anticipated spinal cord stimulation (SCS) device replacement procedures in the fourth quarter of 2024. - Cash, cash equivalents and short-term investments are expected to total approximately
$292.5 million $15.5 million
"We are pleased that our full-year 2024 worldwide revenue is coming in ahead of our expectations," said Kevin Thornal, Nevro's CEO and president. "Also, as we previously communicated, we reallocated investments to our direct-to-consumer (DTC) advertising efforts in the third quarter of 2024, and we continue to see patient interest and response as a result. We anticipate that the benefit from our DTC advertising will ramp throughout 2025, with a more meaningful impact in the second half of the year. Importantly, our balance sheet remains strong, reflecting our continued focus on working capital management and the benefits from our 2024 restructurings."
The company expects to report its fourth-quarter and full-year 2024 financial results and provide full-year 2025 guidance on its fourth-quarter 2024 earnings call in early March 2025.
Strategic Review Process
As previously announced, Nevro remains in ongoing discussions as it continues to explore strategic options to accelerate its growth, diversify its product portfolio and deliver shareholder value. The company will not provide any further comment or update on this process at this time.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in
Nevro also provides minimally invasive treatment options for patients suffering from chronic sacroiliac joint ("SI joint") pain and offers the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.
Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with Nevrocloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, Nevrocloud, RELIEF MULTIPLIED, HFX AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents. Bluetooth® and the Bluetooth symbol are registered trademarks of their respective owners.
To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements reflecting the current beliefs and expectations of the company's management, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: expected fourth quarter 2024 U.S. and worldwide revenue; expected full-year 2024 U.S. and worldwide revenue; expected cash, cash equivalents and short-term investments; the impact of SCS device replacement procedures; the impact of our DTC advertising efforts; our belief that the actions we have taken and intend to take will further position us for growth, success, profitability and value creation; our belief that evaluating and/or engaging in strategic opportunities will help us diversify and grow our business, which we believe may position us to accelerate our goals of profitability and maximizing shareholder value; and our beliefs with regards to the SCS market and factors impacting our results, including the duration in which those factors will continue to impact our results. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth and the costs and expenses of operating our business; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to successfully integrate any additive acquisitions we may make, including our acquisition of Vyrsa™ Technologies; our ability to attract and retain qualified personnel; our ability to accurately forecast financial and operating results; our ability to successfully evaluate and execute on potential strategic opportunities; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 23, 2024, as well as any reports that we may file with the Securities and Exchange Commission in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Nevro's operating results for the period ending December 31, 2024, are not necessarily indicative of the company's operating results for any future periods.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-preliminary-fourth-quarter-and-full-year-2024-revenue-results-302348849.html
SOURCE Nevro Corp.
FAQ
What was Nevro's (NVRO) Q4 2024 revenue performance?
How much did Nevro's (NVRO) cash position increase in Q4 2024?
What is Nevro's (NVRO) full-year 2024 revenue expectation?
When will Nevro (NVRO) provide full-year 2025 guidance?
What drove Nevro's (NVRO) better-than-expected full-year 2024 revenue?
